Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker)
- 1 February 2004
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 93 (2-3) , 105-111
- https://doi.org/10.1016/j.ijcard.2003.10.001
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialThe Lancet, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart FailureCirculation, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart FailureCirculation, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Tissue Renin-Angiotensin System in Myocardial Hypertrophy and FailureArchives of internal medicine (1960), 1993
- The Combination of Estimates from Different ExperimentsPublished by JSTOR ,1954